Biotechnology Technology Articles & Analysis
17 news found
This path-breaking move sees the integration of cutting-edge technology with state-of-art research facilities to amplify the possibilities of devising effective remedies for rare diseases. ...
Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date. The round was co-led by 4BIO Capital and Pureos Bioventures, with participation from new investors, including Wille AG and the ...
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that the company will present data on Araris’ linker technology at the 13th Annual World ADC Conference in San Diego. The poster presentation, titled, "Inducing complete and long-lasting tumor eradications of a nectin-4 ADC generated with a novel linker technology,” ...
This spinning process is very useful in the context of EsoCap’s novel drug delivery technology, enabling targeted and long-lasting local therapy of the esophagus. ...
We appreciate the support of the NJEDA in facilitating our commitment to developing and commercializing products that are helping to save lives.” The New Jersey Technology Business Tax Certificate Transfer Program enables approved Technology and Biotechnology Businesses with Net Operating Losses to sell their Unused Net Operating Loss ...
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that Philipp Probst, Ph.D., Associate Director of ADC Research at Araris, will present data on the company’s linker technology at the 12th Annual World ADC London Conference. The poster presentation, titled, "Broadening the therapeutic index of antibody-drug conjugates ...
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that Philipp Probst, Ph.D., Associate Director of ADC Research at Araris, will present data on the company’s linker technology at the 12th Annual World ADC London Conference. The poster presentation, titled, "Broadening the therapeutic index of antibody-drug conjugates ...
Berkshire Biomedical Corporation (“Berkshire” or “the Company”), focused on developing drug delivery devices designed to accurately and precisely deliver oral liquid drugs only to the biometrically authenticated Intended User, provide remote monitoring and enhance patient wellness, announced today that John Timberlake, Chief Executive Officer of Berkshire Biomedical, will ...
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, announced the appointment of Patrick J. Fowler as Senior Vice President, Corporate Development and Strategy, effective today. Mr. Fowler joins Vericel with over 15 years of business development, strategy and commercial operations experience in the biotech and medical technology ...
“ “I am greatly impressed by the demonstration of EsoCap technology’s functionality and acceptance,” said Dr. Werner Tschollar, President of the Board of EsoCap. ”The EsoCap technology has broad potential in various clinical indications, offering new treatment options for diseases of the ...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has entered into a definitive agreement to acquire Mesa Biotech, Inc., a privately held molecular diagnostic company, for approximately $450 million in cash. Under the terms of the agreement, Thermo Fisher will pay up to an additional $100 million in cash upon the completion of certain milestones ...
Cleveland Diagnostics has a pipeline of simple, cancer-specific and highly cost effective cancer blood tests using the same proprietary core technology. “The traditional approach to early detection strategies for prostate cancer based on standard serum PSA testing is limited by relatively poor diagnostic accuracy and predictive value. ...
“We have set up clinical sites in a matter of hours due to the ease-of-use of the IsoPSA technology.” Dr. Klein has no personal financial interest in the company. ...
Thermo Fisher Scientific, the world leader in serving science, today sponsored the first China-U.S. Precision Medicine Summit, along with co-hosts CEO Roundtable on Cancer, China Academy of Medical Sciences and Peking Union Medical College. The Summit convened more than 400 leaders from across government, academia and industry to promote partnership and collaboration that will lead to advances in ...
While major cities across the country have built reputations as leaders in the health care market, the Madison area has positioned itself as an emerging center for health innovation. Smaller, yes, but the hub of activity is arguably as robust as other rising markets including Austin, Texas, Salt Lake City and Seattle. Wisconsin’s capital city and surrounding region are home to a network of ...
” The multicenter study compared the diagnostic accuracy of Cleveland Diagnostics’ IsoPSA™ technology to PSA, the current standard in prostate cancer, in men scheduled for prostate biopsy. ...
SAN FRANCISCO, CA--(Marketwired - Jun 2, 2015) - US Equity Holdings announced today that it has secured funding to launch Aelan Cell Technologies, a biotech startup engaged in the research, discovery, development and commercialization of innovative biomedical technologies and diagnostic tools for the advancement of human health and longevity. US Equity Holdings Chairman and CEO Chester Aldridge ...